

Changes in the Immunization Schedule Recommended by the Japan Pediatric Society, Jan 26, 2026



- DPT-IPV has been removed from the vaccination schedule because DPT-IPV is no longer manufactured (the final lot expired on December 12, 2025).
- The HPV vaccine schedule has been updated, with separate schedule for males and females.
- Perspective of the Japan Pediatrics Society/Precautions now separate schedule for males and females, and include an update regarding the expanded indication for the 9-valent HPV vaccine for males aged 9 years and older.
- The list of the COVID-19 vaccines available in Japan has been updated to include the use of SPIKEVAX® as a booster dose for individuals aged 6 months to 4 years. Additionally, SPIKEVAX® has changed from a single vial formulation for all age groups to two syringe formulations: one for ages 6 months to 11 years and another for ages 12 years and older.
- Discontinued the publication of antigen strain information in the list of the COVID-19 vaccines available in Japan.

Vaccination Schedule Recommended by the Japan Pediatric Society Jan 26, 2026 Japan Pediatric Society



| Vaccine | | Type | Infant | | | | | | | | | Early Childhood | | | | | | | School Age | | | | | | | | |
|--|------------------------------|-------------|--------|----|----|----|--------------|--------------|----|----|----|---------------------|--|---------------------------------------|--------|----|----------|----|------------|----------|---------------|-------|---------------------------------------|-------------------------------------|---------------|--|--|
| | | | Birth | 6w | 2m | 3m | 4m | 5m | 6m | 7m | 8m | 9-11m | 12-15m | 16-17m | 18-23m | 2y | 3y | 4y | 5y | 6y | 7y | 8y | 9y | ≥10y | | | |
| Hepatitis B virus (HBV) | Universal | Inactivated | | | ① | ② | | | | | ③ | | (Footnote 1) | | | | | | | | | | | | | | |
| | Mother-to-child Transmission | | ① | ② | | | | | ③ | | | | | | | | | | | | | | | | | | |
| Rotavirus | Mono-valent | Live | | | ① | ② | (Footnote 2) | | | | | | | | | | | | | | | | | | | | |
| | Penta-valent | | | | ① | ② | ③ | (Footnote 3) | | | | | | | | | | | | | | | | | | | |
| Pneumococcal (PCV15, PCV20) | | Inactivated | | | ① | ② | ③ | | | | | ④ | | | | | | | | | | | | | | (Footnote 4) | |
| DPT-IPV-Hib | | Inactivated | | | ① | ② | ③ | | | | | | ④ | | | | | | | | | | | | | available <15 yrs | |
| Diphtheria, Pertussis, Tetanus (DPT) | | Inactivated | | | | | | | | | | | | | | | | | ① | | | | | | | | |
| Diphtheria, Tetanus (DT) | | Inactivated | | | | | | | | | | | | | | | | | | | ①11yrs | 12yrs | | | | | |
| Inactivated polio virus (IPV) | | Inactivated | | | | | | | | | | | | | | | ① | | | | | | | | | | |
| Haemophilus influenzae type b *If Hib® is used as first vaccination | | Inactivated | | ① | ② | ③ | | | | | | ④ | | | | | | | | | | | | | | (Footnote 8) | |
| BCG | | Live | | | | | ① | | | | | | | | | | | | | | | | | | | | |
| Measles, Rubella (MR) | | Live | | | | | | | | | | | ① | | | | ② | | | | | | | | | | |
| Varicella | | Live | | | | | | | | | | ① | | ② | | | | | | | | | | | | (Footnote 11) | |
| Mumps | | Live | | | | | | | | | | ① | | | | ② | | | | | | | | | | | |
| Japanese Encephalitis | | Inactivated | | | | | | | | | | available from 6mos | | ① | ③ | | <7.5 yrs | | | ④9-12yrs | | | | | | | |
| Influenza, Inactivated | | Inactivated | | | | | | | | | | available from 6mos | | Annually (October, November, etc.) ①② | | | | | | | | | | | | ① ≥13yrs | |
| Influenza, Live attenuated intranasal | | Live | | | | | | | | | | | | | | | | | | | | | | | | | |
| COVID-19 | | mRNA | | | | | | | | | | | Eligible age range varies by COVID-19 vaccine products | | | | | | | | | | | | | | |
| | | Inactivated | | | | | | | | | | | | | | | | | | | | | | | | | |
| Human papilloma virus (HPV) | female 9-valent | Inactivated | | | | | | | | | | | | | | | | | | | (Footnote 13) | Gr.6 | Junior High Gr.1 ①② (footnote 14) | Junior High Gr.2 – High School Gr.1 | (Footnote 15) | | |
| | | Inactivated | | | | | | | | | | | | | | | | | | | (Footnote 13) | Gr.6 | Junior High Gr.1 ①②③ (footnote 14) | Junior High Gr.2 – High School Gr.1 | (Footnote 15) | | |
| | male 9-valent | Inactivated | | | | | | | | | | | | | | | | | | | | | | | | Junior High Gr.1 ①② (footnote 16,17) | |
| | | Inactivated | | | | | | | | | | | | | | | | | | | | | | | | Junior High Gr.1 ①②③ (footnote 16,17) | |
| Vaccine | | Type | Birth | 6w | 2m | 3m | 4m | 5m | 6m | 7m | 8m | 9-11m | 12-15m | 16-17m | 18-23m | 2y | 3y | 4y | 5y | 6y | 7y | 8y | 9y | ≥10y | | | |

 Recommended age range for routine vaccination

 Period possible for routine vaccination

 Recommended age range for voluntary vaccination

 Period possible for voluntary vaccination

 Not stated in package insert but recommended by the Japan Pediatric Society

 Period for the national health insurance coverage

Vaccination Schedule Recommended by the Japan Pediatric Society Jan 26, 2026

Standard Period, Perspective of the Japan Pediatric Society, Precautions

 Routine Vaccination
  Voluntary Vaccination
  By Health Insurance



| Vaccine | Type | Standard Age of Vaccination and Period | Perspective of the Japan Pediatrics Society | Precautions |
|--|-------------|--|--|--|
| Hepatitis B Virus (HBV) Universal Vaccine | Inactivated | <ul style="list-style-type: none"> ① 2 mos ② 3 mos ③ 7-8 mos ≥27 days (4 wks) interval between ①-② ≥139 days (20 wks) interval between ①-③ | If there is a hepatitis B virus carrier in the family other than the mother, early vaccination is recommended instead of waiting until the child is 2 mos old. | <ul style="list-style-type: none"> • (Footnote 1) For vaccination to prevent horizontal transmission in children who were not vaccinated in infancy, vaccination intervals are the same as for universal vaccines. |
| Hepatitis B Virus (HBV) Vaccines for Prevention of Mother to Child Transmission | Inactivated | <ul style="list-style-type: none"> ① At birth ② 1 mo ③ 6 mos | | <ul style="list-style-type: none"> If a mother is positive for HBs antigen, • The child receives vaccine and HB immunoglobulin simultaneously at birth. • Vaccine fee is covered by the national health insurance (Excluded from routine vaccination coverage). • See in details at "New strategies for the prevention of mother to child transmission of HBV (in Japanese)" on the website of the Japan Pediatric Society. http://www.jpeds.or.jp/modules/activity/index.php?content_id=141 |
| Rotavirus | Live | <ul style="list-style-type: none"> ① Recommended between 8 wks and under 15 wks (Vaccination possible from 6 wks after birth). <ul style="list-style-type: none"> • RV1 vaccine (Rotarix®): For ①-②, a total of 2 doses with an interval of ≥4 wks. • RV5 vaccine (RotaTeq®): For ①-②-③, a total of 3 doses with ≥4 wks between doses. | As a general rule, we do not recommend the first dose of vaccination after 15 wks of age because of the increase in risk of intussusception within 7 days of first vaccination. | <ul style="list-style-type: none"> • (footnote 2) Total 2 doses, ② to be completed within 24th wks of age. • (footnote 3) Total 3 doses, ③ to be completed within 32nd wks of age. • Priority is given to completing the series with the same vaccine, because interchangeability of RV1 and RV5 has not been confirmed yet. • Re-vaccination after vomiting the vaccine is not approved as routine vaccination. Please refer to the "Q&A for Rotavirus Vaccine" published by the Japan Association of Vaccine Industries for more details (in Japanese). https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryou/kenkou/index_00001.html • See "Guideline for Vaccination of the Immunocompromised Host 2024 (in Japanese)" for details on rotavirus vaccinations in children whose mother received treatment with biological products during pregnancy. |
| Pneumococcal, Conjugate (PCV) | Inactivated | <ul style="list-style-type: none"> ≥27 days (4 wks) interval between ①-②-③ ≥60 days (2 mos) interval between ③-④ and administered when the child is 1 yr - 1 yr 3 mos. | Refer to "Considerations for the routine vaccination of PCV in children (in Japanese)". https://www.jpeds.or.jp/uploads/files/20241029_haienq.pdf | <ul style="list-style-type: none"> • If first dose administered between 7 mos-11 mos: ③ can be administered after an interval of ≥60 days following ② and after 1 yr of age. • If first dose administered between 1 yr-23 mos: ≥60 days interval between ①-② . If the first dose administered between 2 yrs and 4 yrs: only ①. • (Footnote 4) Regarding the schedule of voluntary vaccinations, please refer to the "Vaccination of Children (under 15 yrs) with Voluntary Vaccines (in Japanese)" on the website of the Japan Pediatric Society. http://www.jpeds.or.jp/modules/activity/index.php?content_id=316 |

Vaccination Schedule Recommended by the Japan Pediatric Society Jan 26, 2026

Standard Period, Perspective of the Japan Pediatric Society, Precautions

 Routine Vaccination
  Voluntary Vaccination
  By Health Insurance



| Vaccine | Type | Standard Age of Vaccination and Period | Perspective of the Japan Pediatrics Society | Precautions |
|--|-------------|--|---|--|
| DPT-IPV-Hib | Inactivated | Intervals for ①-② and ②-③ are 20-56 days (3-8 wks) For ③-④, ≥6 mos interval is necessary (generally, ④ is given by 18 mos after ③) | ④ is recommended to be vaccinated as early as possible, at least 6 mos after ③ and beyond the age of 1 yr. | DPT-IPV-Hib vaccine is limited to four doses and cannot be used as a booster dose before elementary school |
| Diphtheria, Pertussis, Tetanus (DPT) | Inactivated | Intervals for ①-② and ②-③ are 20-56 days (3-8 wks) For ③-④, ≥6 mos interval is necessary (generally, ④ is given by 12-18 mos after ③) | ④ is recommended to be vaccinated as early as possible, at least 6 mos after ③ and beyond the age of 1 yr. | |
| Diphtheria, Pertussis, Tetanus (DPT) (For the prevention pertussis after entering elementary school) | | ⑤ ≥5 yrs, <7 yrs, ≥6 mos between ④-⑤ ⑥ 11-12 yrs | (Footnote 5) Because of the decline in pertussis antibody titers in children around 10 yrs old, it is recommended that the DPT vaccine given as a booster dose at preschool when four doses of DPT, DPT-IPV, or DPT-IPV-Hib vaccine have been administered. (Footnote 6) It is possible to use DPT vaccine instead of DT vaccine to prevent pertussis. | 0.5 mL per dose |
| Diphtheria, Tetanus (DT) | Inactivated | ①: At 11 yrs until reaching 12 yrs | | • According to the Immunization Law, ≥11 yrs, <13 yrs. |
| Inactivated poliovirus (IPV) | Inactivated | Intervals for ①-② and ②-③ are 20-56 days (3-8 wks) For ③-④, ≥6 mos interval is necessary (generally, ④ is given 12-18 mos after ③) | ④ is recommended to be vaccinated as early as possible, at least 6 mos after ③ and beyond the age of 1 yr. | |
| Inactivated poliovaccine (IPV) (For the prevention polio after entering elementary school) | Inactivated | ⑤ ≥5 yrs, <7 yrs | (Footnote 7) is recommended as a booster dose of inactivated polio vaccine at entering elementary school, before antibody titer against polio decreases. | 0.5 mL per dose |
| Haemophilus influenzae type b (Hib) | Inactivated | 27-56 days (4-8 wks) interval between ①-②-③ 7-13 mos interval between ③-④ | ④ should be given ≥7 mos after ③, and as soon as possible after the age of 1 yr. | • If the first dose is administered between 7 mos and 11 mos: ≥27 (20) days interval between ①-②, and the typical interval between ①-② is 27-56 days (4-8 wks). ≥7 mos interval between ②-③, and the typical interval between ②-③ is 7-13 mos. • If the first dose is administered between 1 yr and 4 yrs: only ①. (Footnote 8) Vaccine can be administered for children ≥5 yrs if they have a risk factors. |

Vaccination Schedule Recommended by the Japan Pediatric Society Jan 26, 2026

Standard Period, Perspective of the Japan Pediatric Society, Precautions

 Routine Vaccination Voluntary Vaccination By Health Insurance

| Vaccine | Type | Standard Age of Vaccination and Period | Perspective of the Japan Pediatrics Society | Precautions |
|-----------------------|-------------|---|--|--|
| BCG | Live | Administered under 12 mos of age, generally administered during the period from 5 mos to <8 mos. | Early vaccination required in areas where incidence of tuberculosis is high. | |
| Measles, Rubella (MR) | Live | ①: 1 yr - <2 yrs ②: ≥5 yrs - <7 yrs (footnote 9) 1 year before entering elementary school | | <ul style="list-style-type: none"> Vaccination possible ≥6mos for post-exposure prophylaxis; however, the vaccine is not counted, regular ① and ② need to be vaccinated. (footnote 10) There was a period in 2024 when there was a shortage of measles and rubella vaccines, and some children were unable to receive the vaccine (the 1st period: children born between April 2, 2022 and April 1, 2023, the 2nd period: children born between April 2, 2018 and April 1, 2019) . These people will be able to receive the MR vaccine as a routine vaccination without cost for two years, from April 1, 2025 to March 31, 2027.(for details, refer to the administrative communication of the Ministry of Health, Labour and Welfare (in Japanese)) https://www.mhlw.go.jp/content/10900000/001440529.pdf |
| Varicella | Live | ①: 12-15 mos ②: 6-12 mos after ① | (Footnote 11) It is necessary to provide 2 doses of varicella vaccine for children who are not suffered from varicella and unvaccinated. | <ul style="list-style-type: none"> ①-②: Leave an interval of ≥3 mos as a routine vaccination. ①-②: Leave an interval of ≥3 mos if ≥3 yrs - <13 yrs (voluntary vaccination) ①-②: Leave an interval of ≥4 wks if ≥13 yrs (voluntary vaccination) |
| Mumps | Live | ①: ≥1 yr ② : ≥5 yrs - <7 yrs | (Footnote 12) To ensure vaccine efficacy, 2 doses are necessary. ①: early vaccination at 1 yr of age ②: simultaneous administration with the 2 nd dose of MR (≥5 yrs - <7 yrs, 1 year before entering elementary school is recommended). | |
| Japanese Encephalitis | Inactivated | ①, ②: 3 yrs, leave a 6-28 days (1-4 wks) interval between ①-② ③: 4 yrs, leave a year after ② ④: 9 yrs | JE vaccine is recommended from 6 mos of age in children who will travel or stay in the endemic area of JE, or live in the area where high prevalence of JE antibody in pigs. "Recommendation for JE vaccine from 6 mos of age in children with high risks for JE (in Japanese)" . http://www.jpeds.or.jp/modules/activity/index.php?content_id=207 | <ul style="list-style-type: none"> A dose per vaccination: 6 mos- <3 yrs: 0.25 mL; ≥3 yrs: 0.5 mL For general routine vaccinations, first set administered from 6 mos to under 90 mos (7.5 yrs), and second set at age 9 to under 13 yrs. Interval of ≥6 days between ①-②, ≥6 mos between ② and ③. For children who were born from April 2, 1995 to April 1, 2007, it is possible to receive vaccine as a routine vaccine if they did not receive 1st stage (①, ②, ③) during 6 mos-<90 mos (7 yr 6 mos) or 9 yrs to <13 yrs. Due to the assertive recommendation to refrain from administration in May 2005, a detailed schedule for those who were born between April 2, 1995 and October 1, 2007 (in Japanese) . https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_ryou/kekaku-kansenshou/yobou-sesshu/vaccine/japanese-encephalitis/index.html |

Vaccination Schedule Recommended by the Japan Pediatric Society Jan 26, 2026

Standard Period, Perspective of the Japan Pediatric Society, Precautions

 Routine Vaccination
  Voluntary Vaccination
  By Health Insurance



| Vaccine | | Type | Standard Age of Vaccination and Period | Perspective of the Japan Pediatrics Society | Precautions |
|--|--------|---------------------|--|--|--|
| Influenza, Inactivated | | Inactivated | Leave an interval of 4 wks between ① and ② (2-4 wks) | | <ul style="list-style-type: none"> <13 yrs: 2 doses, ≥13 yrs: 1 or 2 doses (basically 1 dose). Single dose: 6 mos - <3 yrs: 0.25 mL; ≥3 yrs: 0.5 mL. |
| Influenza, Intranasal live attenuated | | Live | 2 yrs -<19 yrs, ① in each influenza season | <p>Live attenuated Influenza vaccine is equally recommended as inactivated Influenza vaccine, except for individuals such as those with asthma, immunocompromised condition.</p> <p>Please refer to "Considerations for the use of intranasal live attenuated influenza vaccine" for details.</p> <p>https://www.jpeds.or.jp/modules/activity/index.php?content_id=607</p> | <p>0.2 mL per dose, intranasally sprayed, 1 dose in every influenza season. (Spray of 0.1 mL in each nostril, a total of two sprays)</p> <p>There is no description to limit the interval between live attenuated influenza vaccine and other vaccine administrations in the vaccine package inserts.</p> |
| COVID-19 | | mRNA Inactivated | Vaccination according to the schedule for specified for each formulation. | | Refer to "List of COVID-19 vaccines available in Japan" and each vaccine package inserts. |
| Human Papilloma Virus (HPV) | female | Inactivated | <p>Junior high school Grade 1</p> <ul style="list-style-type: none"> HPV9 vaccine (SILGARD®9): When received < 15 yrs, 2 doses recommended, generally leave 6 mos to 12 mos between ①-②. However, if it is not possible to leave this interval, the second dose can be administered if there is an interval of at least 5 mos between ①-②. | <p>If HPV2 or HPV4 was used for the initial vaccination, the same vaccine should be used as a booster. However, HPV9 can also be used as a booster.</p> | <ul style="list-style-type: none"> Vaccine given as intramuscular injection (upper arm, deltoid area). By the Immunization Law, 12-16 yrs (elementary school grade 6 to high school year 1) female. (Footnote 13) HPV2 vaccine can be administered from ≥10 yrs, and HPV4 and 9 vaccine can be administered from ≥9 yrs. (Footnote 14) Vaccination is possible as routine vaccination with the interval below if not administered in the regular schedule (Note the difference in the interval required for routine vaccination between the 3 vaccines). <ul style="list-style-type: none"> HPV9 vaccine (start from ≥15 yrs): ≥1 mo between ①-②, and ≥3 mos between ②-③. HPV2 vaccine: ≥1 mo between ①-②; ≥5 mos between ①-③ and ≥2.5 mos between ②-③. HPV4 vaccine: ≥1 mo between ①-②, and ≥3 mos between ②-③. <p>(Footnote 15) If women who were born between 1997 and 2008 (Japanese academic year) and those who received at least one dose of HPV vaccine between April 1, 2022 and March 31, 2025 can receive the second and third doses of vaccine until March 31, 2026 at public expense if they wish to receive. For details, please refer to the website of the Ministry of Health, Labor and Welfare.</p> <p>https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou/hpv_catch-up-vaccination.html</p> |
| | male | Inactivated | <p>Junior high school Grade 1</p> <ul style="list-style-type: none"> HPV9 vaccine (SILGARD®9): When received < 15 yrs, 2 doses recommended, generally leave 6 mos to 12 mos between ①-②. However, if it is not possible to leave this interval, the second dose can be administered if there is an interval of at least 5 mos between ①-②. | <ul style="list-style-type: none"> (Footnote 16) Male ≥9 yrs can receive 3 doses of HPV4 or HPV9 as a voluntary vaccine. When using HPV9, two doses (leave 6 mos to 12 mos between ①-②) are sufficient for individuals aged 9 to under 15 years. | <ul style="list-style-type: none"> Vaccine given as intramuscular injection (upper arm, deltoid area). (Footnote 17) Vaccination is possible with the interval below if not administered in the regular schedule (Note the difference in the interval required for routine vaccination between the 2 vaccines). <ul style="list-style-type: none"> HPV9 vaccine (start from ≥15 yrs): ≥1 mo between ①-②, and ≥3 mos between ②-③. HPV4 vaccine: ≥1 mo between ①-②, and ≥3 mos between ②-③. |

Immunization Check List

Name : _____ Date of Birth : _____ / _____ / _____ Routine vaccine Voluntary vaccine Voluntary vaccine

| Vaccines | Type | Dose 1 | Dose 2 | Dose 3 | Dose 4 | Dose 5 | Dose 6 |
|--|---------------------|--|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|
| Hepatitis B (HBV) | Inactivated | <input type="checkbox"/> (/ /) | <input type="checkbox"/> (/ /) | <input type="checkbox"/> (/ /) | | | |
| Rotavirus | Live | <input type="checkbox"/> (/ /) | <input type="checkbox"/> (/ /) | <input type="checkbox"/> (/ /) | | | |
| Pneumococcal conjugate (PCV15,PCV20) | Inactivated | <input type="checkbox"/> (/ /) | <input type="checkbox"/> (/ /) | <input type="checkbox"/> (/ /) | <input type="checkbox"/> (/ /) | <input type="checkbox"/> (/ /) | |
| DPT-IPV-Hib or DPT-IPV or DPT+IPV | Inactivated | <input type="checkbox"/> (/ /) | <input type="checkbox"/> (/ /) | <input type="checkbox"/> (/ /) | <input type="checkbox"/> (/ /) | | |
| Diphtheria, Pertussis, Tetanus (DPT) (post school age prevention for pertussis) | Inactivated | | | | | <input type="checkbox"/> (/ /) | <input type="checkbox"/> (/ /) |
| Diphtheria, Tetanus (DT) | Inactivated | | | | | <input type="checkbox"/> (/ /) | |
| Polio (post school age prevention for polio) | Inactivated | | | | | <input type="checkbox"/> (/ /) | |
| Haemophilus influenzae type b (Hib) | Inactivated | <input type="checkbox"/> (/ /) | <input type="checkbox"/> (/ /) | <input type="checkbox"/> (/ /) | <input type="checkbox"/> (/ /) | | |
| BCG | Live | <input type="checkbox"/> (/ /) | | | | | |
| Measles, Rubella (MR) | Live | <input type="checkbox"/> (/ /) | <input type="checkbox"/> (/ /) | | | | |
| Varicella | Live | <input type="checkbox"/> (/ /) | <input type="checkbox"/> (/ /) | | | | |
| Mumps | Live | <input type="checkbox"/> (/ /) | <input type="checkbox"/> (/ /) | | | | |
| Japanese encephalitis | Inactivated | <input type="checkbox"/> (/ /) | <input type="checkbox"/> (/ /) | <input type="checkbox"/> (/ /) | <input type="checkbox"/> (/ /) | | |
| Influenza | Inactivated or Live | (Annual vaccination is recommended, please refer to the Influenza Vaccination checklist) | | | | | |
| COVID-19 | mRNA or Inactivated | (Annual vaccination is recommended, please refer to the COVID-19 Vaccination checklist) | | | | | |
| Human papillomavirus (HPV) | Inactivated | <input type="checkbox"/> (/ /) | <input type="checkbox"/> (/ /) | <input type="checkbox"/> (/ /) | | | |

Two doses are the maximum for those who started the 9-valent vaccine (Silgard®9) under the age of 15.

The 2-valent vaccine (Cervarix®) and 4-valent vaccine (Gardasil®) require three doses. The 9-valent vaccine (Silgard®9) also requires three doses if started at age 15 or older.

Influenza Vaccination Checklist

| Name : _____ | | | Date of Birth : / / | | |
|--------------|--|--|---------------------------|--|--|
| Age | Dose 1 | Dose 2 | Age | Dose 1 | Dose 2 |
| 6-11 mos | <input type="checkbox"/> Inactivated (/ /) | <input type="checkbox"/> Inactivated (/ /) | 8 yrs | <input type="checkbox"/> Inactivated <input type="checkbox"/> Live (/ /) | <input type="checkbox"/> Inactivated (/ /) |
| 1 yr | <input type="checkbox"/> Inactivated (/ /) | <input type="checkbox"/> Inactivated (/ /) | 9 yrs | <input type="checkbox"/> Inactivated <input type="checkbox"/> Live (/ /) | <input type="checkbox"/> Inactivated (/ /) |
| 2 yrs | <input type="checkbox"/> Inactivated <input type="checkbox"/> Live (/ /) | <input type="checkbox"/> Inactivated (/ /) | 10 yrs | <input type="checkbox"/> Inactivated <input type="checkbox"/> Live (/ /) | <input type="checkbox"/> Inactivated (/ /) |
| 3 yrs | <input type="checkbox"/> Inactivated <input type="checkbox"/> Live (/ /) | <input type="checkbox"/> Inactivated (/ /) | 11 yrs | <input type="checkbox"/> Inactivated <input type="checkbox"/> Live (/ /) | <input type="checkbox"/> Inactivated (/ /) |
| 4 yrs | <input type="checkbox"/> Inactivated <input type="checkbox"/> Live (/ /) | <input type="checkbox"/> Inactivated (/ /) | 12 yrs | <input type="checkbox"/> Inactivated <input type="checkbox"/> Live (/ /) | <input type="checkbox"/> Inactivated (/ /) |
| 5 yrs | <input type="checkbox"/> Inactivated <input type="checkbox"/> Live (/ /) | <input type="checkbox"/> Inactivated (/ /) | 13 yrs | <input type="checkbox"/> Inactivated <input type="checkbox"/> Live (/ /) | |
| 6 yrs | <input type="checkbox"/> Inactivated <input type="checkbox"/> Live (/ /) | <input type="checkbox"/> Inactivated (/ /) | 14 yrs | <input type="checkbox"/> Inactivated <input type="checkbox"/> Live (/ /) | |
| 7 yrs | <input type="checkbox"/> Inactivated <input type="checkbox"/> Live (/ /) | <input type="checkbox"/> Inactivated (/ /) | 15 yrs | <input type="checkbox"/> Inactivated <input type="checkbox"/> Live (/ /) | |

Live attenuated influenza vaccine is administered as a single dose each influenza season.

COVID-19 Vaccination Checklist

Number of doses differs by COVID-19 vaccine products and the purpose of vaccination.

Name :

| Age | | | | |
|----------|--|---------------|--------------------------|---------------|
| 6-11 mos | Product name <input type="checkbox"/> | (/ /) | <input type="checkbox"/> | (/ /) |
| | Date | (/ /) | <input type="checkbox"/> | (/ /) |
| 1 yr | Product name <input type="checkbox"/> | (/ /) | <input type="checkbox"/> | (/ /) |
| 2 yrs | Product name <input type="checkbox"/> | (/ /) | <input type="checkbox"/> | (/ /) |
| 3 yrs | Product name <input type="checkbox"/> | (/ /) | <input type="checkbox"/> | (/ /) |
| 4 yrs | Product name <input type="checkbox"/> | (/ /) | <input type="checkbox"/> | (/ /) |
| 5 yrs | Product name <input type="checkbox"/> | (/ /) | <input type="checkbox"/> | |
| 6 yrs | Product name <input type="checkbox"/> | (/ /) | <input type="checkbox"/> | |
| 7 yrs | Product name <input type="checkbox"/> | (/ /) | <input type="checkbox"/> | |

Date of Birth : / /

| Age | | | |
|--------|--|---------------|--------------------------|
| 8 yrs | Product name <input type="checkbox"/> | (/ /) | <input type="checkbox"/> |
| 9 yrs | Product name <input type="checkbox"/> | (/ /) | <input type="checkbox"/> |
| 10 yrs | Product name <input type="checkbox"/> | (/ /) | <input type="checkbox"/> |
| 11 yrs | Product name <input type="checkbox"/> | (/ /) | <input type="checkbox"/> |
| 12 yrs | Product name <input type="checkbox"/> | (/ /) | <input type="checkbox"/> |
| 13 yrs | Product name <input type="checkbox"/> | (/ /) | <input type="checkbox"/> |
| 14 yrs | Product name <input type="checkbox"/> | (/ /) | <input type="checkbox"/> |
| 15 yrs | Product name <input type="checkbox"/> | (/ /) | <input type="checkbox"/> |

List of COVID-19 vaccines available in Japan (as of Jan 2026)

| Manufacturer | Trade Name | Modality | Approved Ages | Dosage | Administration Route | Doses and Intervals between doses |
|---------------------------------------|-----------------------------------|------------------------|------------------|------------------|----------------------|--|
| Pfizer Japan Inc. | COMIRNATY for 6 mos to 4 yrs | mRNA | 6 mos - 4 yrs | 0.3 mL per dose | Intramuscular | Initial series (no prior SARS-CoV-2 vaccine) : 3 doses (Dose 1 and Dose 2, 3 weeks apart, Dose 3 at least 8 weeks after Dose 2). Booster (any prior SARS-CoV-2 vaccine) : 1 dose at least 3 months after the last SARS-CoV-2 vaccine. |
| | COMIRNATY for 5 to 11 yrs | mRNA | 5 - 11 yrs | 0.3 mL per dose | Intramuscular | Booster: 1 dose at least 3 months after the last SARS-CoV-2 vaccine. If no prior SARS-CoV-2 vaccine, administer 2 doses approximately 4 weeks apart. |
| | COMIRNATY for 12 yrs and older | mRNA | 12 yrs and older | 0.3 mL per dose | Intramuscular | Booster: 1 dose at least 3 months after the last SARS-CoV-2 vaccine. If no prior SARS-CoV-2 vaccine, administer 2 doses approximately 4 weeks apart. |
| Moderna Japan Co. Ltd | SPIKEVAX for 6 mos to 11 yrs | mRNA | 6 mos - 4 yrs | 0.25 mL per dose | Intramuscular | Initial series (no prior SARS-CoV-2 vaccine) : 2 doses (administer 2 doses 4 weeks apart). Booster (any prior SARS-CoV-2 vaccine) : 1 dose at least 3 months after the last SARS-CoV-2 vaccine. |
| | SPIKEVAX for 12 yrs and older | | 5 - 11 yrs | 0.25 mL per dose | Intramuscular | Booster: 1 dose at least 3 months after the last SARS-CoV-2 vaccine. If no prior SARS-CoV-2 vaccine, administer 2 doses approximately 4 weeks apart. |
| | SPIKEVAX for 12 yrs and older | | 12 yrs and older | 0.5 mL per dose | Intramuscular | Booster: 1 dose at least 3 months after the last SARS-CoV-2 vaccine. If no prior SARS-CoV-2 vaccine, administer 2 doses approximately 4 weeks apart. |
| Daiichi Sankyo Co., Ltd. | DAICHIRONA | mRNA | 5 - 10 yrs | 0.2 mL per dose | Intramuscular | Booster: 1 dose at least 3 months after the last SARS-CoV-2 vaccine. If no prior SARS-CoV-2 vaccine, administer 2 doses approximately 4 weeks apart. |
| | | mRNA | 12 yrs and older | 0.6 mL per dose | Intramuscular | Booster: 1 dose at least 3 months after the last SARS-CoV-2 vaccine. If no prior SARS-CoV-2 vaccine, administer 2 doses approximately 4 weeks apart. |
| Takeda Pharmaceutical Co., Ltd. | NUVAXOVID | Recombinant protein | 6 - 11 yrs | 0.5 mL per dose | Intramuscular | For person with no prior SARS-CoV-2 vaccine: 2 doses typically 3 weeks apart as initial series. |
| | | | 12 yrs and older | 0.5 mL per dose | Intramuscular | Booster: 1 dose <u>at least 6 months</u> after the last SARS-CoV-2 vaccine. If no prior SARS-CoV-2 vaccine, administer 2 doses approximately 4 weeks apart. |
| Meiji Seika Pharma Co., Ltd. | KOSTAIVE | mRNA (replicon) | 18 yrs and older | 0.5 mL per dose | Intramuscular | Booster: 1 dose at least 3 months after the last SARS-CoV-2 vaccine. If no prior SARS-CoV-2 vaccine, administer 2 doses approximately 4 weeks apart. |